ROKIT Healthcare’s bioprinting-based diabetic foot treatment kit registered as a U.S. FDA medical device
Since 2019, the company has conducted clinical studies in India, Korea and Turkey, and based on the most recent study results in the U.S., the treatment has shown promising results in all of the study patients with no side effects.
The company reported that the study subjects were patients of chronic diabetic foot ulcer with an average of 64.4 years of age, 15 years of diabetes duration, and obesity in 90% of the patients.
The principal investigator behind the study is Dr. David G. Armstrong, PhD, DPM, who is Professor of Clinical Surgery at University of Southern California and has produced more than 510 peer-reviewed research papers in scholarly medical journals and 90 book chapters with expertise in the treatment and clinical care of the diabetic foot. Dr. Armstrong is past Chair of Scientific Sessions for the American Diabetes Association’s Foot Care Council and the founder and co-chair of the International Diabetic Foot Conference, the largest annual international symposium on the diabetic foot in the world.
“There is no existing method that resolves chronic diabetic foot ulcers by way of true regenerative medicine, especially for those ulcers that failed to close for many months,” said an official of ROKIT Healthcare. “We have seen our bioprinting-based diabetic foot ulcer treatment offer hope for patients who recovered and got back on their feet within just a few weeks after one procedure, making daily life possible again.
“The clinical study results have demonstrated that ROKIT Healthcare’s diabetic foot ulcer treatment kit can effectively regenerate skin of diabetic foot affected areas regardless of various variables such as race, age, and underlying disease. I can take one more step,” he said.
ROKIT Healthcare’s diabetic foot ulcer treatment, which consists of the printer Dr. INVIVO DFU and patient-specific autologous solution extraction kits, uses 3D scanning and AI-based interpretation of patient wounds to create customized skin regeneration patches.
“Given the FDA medical device registration and several successful global studies yielding promising results, we are proud to be leading a meaningful work of saving human lives with cutting-edge regenerative medicine technologies,” said Seok-Hwan You, CEO of ROKIT Healthcare. “I look forward to contributing to the advancement of chronic ulcer treatment methods and significantly improving the quality of life for patients.”
You May Also Like
ICAM 2021: Keynotes on 3D Printing in Healthcare & Aerospace
At last month’s International Conference on Additive Manufacturing (ICAM) 2021 in Anaheim, California, hosted by ASTM International’s Additive Manufacturing Center of Excellence (AMCOE), a wide variety of topics were covered,...
3D Printing Unicorns: Gelato Gets $240M in Funding, Expands into 3D Printing
On-demand printing platform Gelato, based in Oslo, Norway, achieved the coveted unicorn status after a new funding round. On August 16, 2021, the company announced it had raised $240 million...
US Army and Raytheon to Use 3D Systems Metal 3D Printing to Heat-Optimize Munitions
3D Systems (NYSE: DDD) has been chosen by defense contractor Raytheon and the U.S. Army’s central laboratory to help with a design optimization project. To do that, the 3D Systems’...
Raytheon Receives Funding for Aerospace 3D Printing of Optical Components
This spring, Ohio-based America Makes, the leading collaborative partner in additive technology research, discovery, and innovation for the US, announced its latest Project Call for AXIOM, or Additive for eXtreme Improvement...
View our broad assortment of in house and third party products.